Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE
Por um escritor misterioso
Descrição
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis - Fokkens - 2023 - Allergy - Wiley Online Library
GSK Poster Hub
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
Endotyping Chronic Rhinosinusitis with Nasal Polyps: Understanding Inflammation Beyond Phenotypes - Chongjia C. Chen, Kathleen M. Buchheit, 2023
Mepolizumab may reduce size of nasal polyps, need for surgery in chronic rhinosinusitis
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine
Frontiers Considerations for shared decision-making in treatment of chronic rhinosinusitis with nasal polyps
Mepolizumab reduces risk for repeat surgery for chronic rhinosinusitis with nasal polyps
Managing chronic rhinosinusitis with nasal polyps in elderly
Biologic therapies for chronic rhinosinusitis with nasal polyps: a new paradigm
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count - ScienceDirect
FDA approves GSK's Nucala for use in adults with chronic rhinosinusitis with nasal polyps - PharmaLive
Study Results NUCALA (mepolizumab) for HCPs
de
por adulto (o preço varia de acordo com o tamanho do grupo)
